Ligand partner GlaxoSmithKline announces US regulatory submission for Promactaź
Ligand announced that its partner GlaxoSmithKline reported the submission of a sNDA to the FDA for eltrombopag (Promacta), seeking an additional indication in pediatric patients six years old and older with with chronic immune (idiopathic) thrombocytopenia. December 22, 2014